TRACON Pharmaceuticals WKN: A2PU7C ISIN: US89237H2094 Forum: Aktien Thema: Hauptdiskussion

Geht heut was? Halbe Std soll ja ne Präsentation kommen

Baird Initiates Coverage On TRACON Pharmaceuticals with Outperform Rating, Announces Price Target of $10

Tracon Pharmaceuticals 10%+ Owner Opaleye Management Reported Purchase of 841,989 Shares @ Avg Price of $1.31/Share in Form 4 Filing on Thursday🤔🕰🕰

Kursziel 10$ 🤔

🤔

Noch jemand investiert hier

...

🚀🚀🚀😂😂😂

Bin auch mit dabei , mal schauen was geht .

Wann würd der Deal erwartet , noch in Q1 ?

Ich denke das Risiko ist überschaubar

Wl

TRACON Pharmaceuticals' (TCON) CEO Charles Theuer on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4302914?source=ansh $TCON

Tracon rechnet damit dass ihr Kapital bis in Q3 reicht, spekulierend auf den Janssen-Deal(?) 🤔 Ich gehe weiterhin von Mai/Juni aus. Cash, cash equivalents and short-term investments were $19.1 million at September 30, 2019 compared to $39.1 million at December 31, 2018.  We expect our current cash, cash equivalents and short-term investments to fund operations into the third quarter of 2020.

Expected Upcoming Milestones Top-*** data, including the primary endpoint of mean change in best corrected visual acuity at six months, from the randomized Phase 2 AVANTE trial of DE-122 in patients with wet AMD are expected in the first half of 2020.  In this trial DE-122 is being combined with Lucentis and being compared with Lucentis single agent treatment.   The Phase 2 POC data from the Phase 1/2 clinical trial of TRC253 in metastatic castrate resistant prostate cancer is now expected in the first half of 2020, whereupon Janssen have an exclusive option to reacquire full rights to TRC253 for an opt-in payment of $45 million to TRACON, and obligations to pay regulatory and commercialization milestones totaling up to $137.5 million upon achievement of specified events, in addition to a low single-digit royalty on net sales. If Janssen does not opt in TRACON can advance TRC253 independently, in which case TRACON would owe Janssen up to $45 million upon achievement of specified events, in addition to a low single-digit royalty on net sales. Top *** data for the Phase 1 dose escalation study of TJ004309, a CD73 antibody, as a single agent and in combination with Tecentriq, a marketed PD-L1 antibody being supplied by Roche, is expected in the second half of 2020.  We are developing TJ004309 in collaboration with I-Mab Biopharma.   Nomination and IND filing of the initial bispecific antibody (BsAb) from the I-Mab pipeline is expected in the second half of 2020.  The I-Mab pipeline includes PD-L1 x IL-7, PD-L1 x CD47, PD-L1 x CD73, PD-L1 x B7-H3, and PD-L1 x 4-1BB antibodies. TRACON and I-Mab previously entered into a cost-sharing product development collaboration whereby TRACON will be responsible for the regulatory and clinical development of up to five of the BsAbs in North America and Europe, with the majority of the development effort expected to occur in the U.S. TRACON will bear the costs of early phases of clinical trials and I-Mab will share the costs for more advanced development stages and commercialization. TRACON will share the North America rights of any selected BaAbs with I-Mab for each collaborative program and retains an opt-in right to in-license the BsAbs from I-Mab ex-greater China.